The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
CAH now rates as a covered call candidate.
I continue to see these names as bargains in the biotech and biopharma space.
With most of the consumer product giant's growth concentrated in just one division, breaking up the company likely wouldn't unlock value.
T2 Biosystems' recent run-up on a positive event provides an important lesson for biotech investors.
Quantitatively or technically, PRGO comes up bearish.
Johnson & Johnson is a premiere company, but the trick is knowing when to buy it.
The setup here is appealing enough to take a small, aggressive shot on the long side.
Here's our new strategy for the shares.

Columnist Conversations

SPX-Cash The first short term support @ 2764.41 and holding remains short term bullish. I would still look to...
I caught up with Tyson Foods (TSN) CEO Tom Hayes for an interview on TheStreet that hit on Sunday. Hayes is b...
Gold prices have taken a dive in the wake of the Fed meeting. Interesting move considering how concerned Fed c...


News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.